Myriad Genetics Company Leadership

Myriad Genetics Management Team Effectiveness

The company has return on total asset (ROA) of (0.0567) % which means that it has lost $0.0567 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7252) %, meaning that it created substantial loss on money invested by shareholders. Myriad Genetics' management efficiency ratios could be used to measure how well Myriad Genetics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 30th of January 2026, Return On Tangible Assets is likely to grow to -0.29. In addition to that, Return On Capital Employed is likely to grow to -0.12. At this time, Myriad Genetics' Non Current Assets Total are very stable compared to the past year. As of the 30th of January 2026, Non Currrent Assets Other is likely to grow to about 8 M, while Total Assets are likely to drop about 686.6 M. As of the 30th of January 2026, Common Stock Shares Outstanding is likely to drop to about 75.8 M. In addition to that, Net Income Applicable To Common Shares is likely to drop to about 159.7 MMyriad Genetics maintains a total of 93.21 Million outstanding shares. The majority of Myriad Genetics outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Myriad Genetics to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Myriad Genetics. Please pay attention to any change in the institutional holdings of Myriad Genetics as this could imply that something significant has changed or is about to change at the company. Also note that almost one million nine hundred eighty-five thousand four hundred fifty-two invesors are currently shorting Myriad Genetics expressing very little confidence in its future performance. Some institutional investors establish a significant position in stocks such as Myriad Genetics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Myriad Genetics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Myriad Genetics Workforce Comparison

Myriad Genetics Profit Margins

The company has Profit Margin (PM) of (0.49) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.11) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.11.

Myriad Genetics Insider Trading History

Myriad Genetics Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as Myriad Genetics often depends on how effective the management is. Myriad Genetics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Myriad management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Myriad management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Myriad Genetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.

Will Biotechnology sector continue expanding? Could Myriad diversify its offerings? Factors like these will boost the valuation of Myriad Genetics. Expected growth trajectory for Myriad significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Myriad Genetics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.

Investors evaluate Myriad Genetics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Myriad Genetics' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Myriad Genetics' market price to deviate significantly from intrinsic value.

Understanding that Myriad Genetics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Myriad Genetics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Myriad Genetics' market price signifies the transaction level at which participants voluntarily complete trades.